Would the 2nd battle break out between Trajenta and Januvia due to the beneficiary standard alteration?

While Trajenta (generic name: linagliptin) is catching up, Januvia (generic name: sitagliptin) is running away; the two products dividing the DDP-4 inhibitor market are reviving its endless chase using the alteration of the type II diabetes beneficiary standard as a trigger.

As joint uses of DDP-4 inhibitors and insulins are available due to the alteration of the beneficiary standard, their 2^n...